Q. Two members of our book group have early signs of cognitive impairment. We have become so close after 10 years of being ...

A novel tool known as the Florey Dementia Index (FDI) predicted onset age of mild cognitive impairment or Alzheimer's disease ...

According to DelveInsight's analysis, the mild cognitive impairment market is anticipated to increase during the forecast period (2024-2034), owing to the rise in the launch of emerging therapies ...

Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Predicted ages for the onset of mild cognitive impairment and Alzheimer’s dementia ... the researchers employed data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer (A4) study to ...

A new USC-led study suggests that assessing blood vessel health should be included in dementia diagnostics. A new USC-led ...

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

New research published in Menopause, the journal of The Menopause Society, found a possible link between severe menopause ...

A study examining the effects of virtual reality cognitive training on Chinese adolescents with mild to moderate depression ...